CA-TRICENTIS
Tricentis, the leader in continuous testing for DevOps, announced that it has acquired SpecFlow, the biggest and most trusted BDD solution for .NET developers around the world. SpecFlow’s pragmatic approach to specification-by-example has helped agile development teams improve collaboration with business stakeholders to build and deliver higher quality software.
SpecFlow will continue to remain a free, open source offering for the software development and testing communities. SpecFlow+ , SpecFlow’s commercial offering, and SpecMap , an Azure DevOps extension for user story mapping, will now be offered for free to meet the needs of scaling BDD across the enterprise – all backed by Tricentis’ leading innovation in continuous testing.
With this acquisition, Tricentis continues to extend its leadership in the open source and developer-led testing market. SpecFlow is Tricentis’ second acquisition in this market within the past year, with further acquisitions planned in the coming months. In 2019, Tricentis acquired TestProject , the world’s first free, cloud based test automation platform leveraging Selenium and Appium. The acquisition of SpecFlow adds best-in-class support for BDD and .NET developers to round out Tricentis’ comprehensive open source testing platform.
“BDD is becoming broadly relevant in enterprises for their digital transformation,” explained Tricentis Founder and Chief Strategy Officer Wolfgang Platz. “As business requirements change at DevOps speed, teams need a way to document how their applications should behave across highly integrated systems. Without built-in test automation to this shared understanding, software delivery leads to production bugs and poor user experiences. SpecFlow’s ability to create this shared business understanding, connected with automated tests, makes it the most trusted BDD platform for .NET development.”
SpecFlow was developed by TechTalk as the open source port of Cucumber for .NET in 2009. Since then, SpecFlow has gathered a massive open source community, with more than 9.6 million downloads and a user base that continues to grow at more than 3,000 downloads per day.
SpecFlow provides a way to define, manage and automatically execute human-readable acceptance tests in .NET projects. By using human-readable syntax, known as Gherkin (“Given-When-Then”), SpecFlow helps software delivery teams to create a common business understanding of how their systems should behave. Its integration with popular developer tools like Selenium and Microsoft Visual Studio have made SpecFlow the BDD standard to bridge the communication gap between developers, testers and business users.
“I’m extremely proud of the community that SpecFlow has fostered over the years,” said Christian Hassa, Owner and Managing Partner at TechTalk. “TechTalk is happy to have found a partner in Tricentis who is committed to the BDD community and to significantly expand on our vision for SpecFlow while keeping it independent.”
About SpecFlow
SpecFlow is the world’s leading open-source Behavior-Driven Development framework for .NET. SpecFlow facilitates collaboration between teams in small and large enterprises, allows you to automate tests written in human-readable language, and helps stakeholders build up a shared understanding of software systems. Learn more about SpecFlow at https://specflow.org .
About TechTalk
TechTalk is a Central European company that specializes in agile methods, agile development, and agile coaching. TechTalk was a first mover in the agile community, realized the potential of Behavior-Driven Development at an early stage and started developing SpecFlow in 2008. TechTalk released SpecFlow as an open-source project in 2009 to involve the agile community and accelerate the growth and adoption of SpecFlow. Learn more about TechTalk at https://techtalk.at or follow us on LinkedIn , Twitter .
About Tricentis
With the industry’s #1 Continuous Testing platform, Tricentis is recognized for reinventing software testing for DevOps. Through agile test management and advanced test automation optimized to support over 150+ technologies, we provide automated insight into the business risks of your software releases–transforming testing from a roadblock to a catalyst for innovation. The result is accelerated software delivery speed, improved cost efficiency, and reduced business risk.
Tricentis is the only vendor to achieve “Leader” status in all three top analyst reports (i.e., the “Triple Crown”). This honor is based on our technical leadership, innovation, and a Global 2000 customer base of 1600+ companies, including global enterprises such as Allianz, ANZ Bank, Cisco, Dolby, Experian, First Data, HSBC, Merck, Office Depot, Samsung, Swiss Re, Starbucks, Telstra, UBS, Vodafone, Whole Foods, and WorldPay. Customers rely on Tricentis to achieve and sustain test automation rates of over 90 percent–increasing risk coverage while accelerating testing to keep pace with Agile and DevOps.
Tricentis has a global presence in Austria, Australia, Belgium, Denmark, Germany, India, Netherlands, Singapore, Switzerland, Poland, United States and the UK. To learn more, visit https://www.tricentis.com or follow us on LinkedIn , Twitter , and Facebook .
View source version on businesswire.com: https://www.businesswire.com/news/home/20200115005741/en/
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Welcomes Increased Equity Investment From L’Oréal8.12.2025 07:05:00 CET | Press release
L’Oréal to acquire an additional 10% stake in Galderma recognizing its scientific leadership in dermatology and long-term growth potential Ad hoc announcement pursuant to Art. 53 LR Galderma Group AG (SIX:GALD), the pure-play dermatology category leader, today announced that L’Oréal Groupe intends to increase its equity investment in the company, acquiring an additional 10% stake from Sunshine SwissCo GmbH (a consortium led by EQT, Abu Dhabi Investment Authority (ADIA), and Auba Investment Pte. Ltd., acting as sellers). Following the transaction, which is subject to customary approvals, L’Oréal’s total shareholding in Galderma will rise to 20%, building on its initial investment made in August 2024. The transaction is expected to close in Q1 2026. In connection with this increased investment, Galderma will consider nominating two non-independent board candidates from L’Oréal, replacing the board members representing the consortium led by EQT, at the 2026 Annual General Meeting. Additio
Ant International Wins Champion of NeurIPS Competition of Fairness in AI Face Detection8.12.2025 04:37:00 CET | Press release
The Challenge: Deepfakes undermine both the accuracy and fairness of AI face detection due to variations in human features.The Technology: Ant International’s AI model uses a novel ‘Mixture of Experts’-based Adversarial Debiasing approach to achieve superior fairness and accuracy across diverse demographics.The Impact: This advancement strengthens payment security, offering robust protection against deepfake fraud and enhancing eKYC compliance globally. Ant International, a leading global digital payment, digitisation, and financial technology provider, has won first place at the NeurIPS Competition of Fairness in AI Face Detection. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207210856/en/ Ant International’s solution takes top spot at the NeurIPS Competition of Fairness in AI Face Detection, emerging first among over 2,100 submissions from 162 teams globally. AI Fairness enhances Financial Security Studies by the Nati
Sonrotoclax Data at ASH 2025 Confirm Foundational Potential Across B-cell Malignancies8.12.2025 00:00:00 CET | Press release
Novel BCL2 inhibitor sonrotoclax monotherapy demonstrates deep and durable clinical responses in R/R MCL and R/R CLLSonrotoclax in combination with BRUKINSA demonstrated rapid MRD negativity in treatment-naive CLL, regardless of high-risk features BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data on sonrotoclax, a next-generation investigational BCL2 inhibitor, demonstrating meaningful clinical benefit as monotherapy and in combination across B-cell malignancies. These data were featured at the 67th American Society of Hematology (ASH) Annual Meeting & Exposition in Orlando, Florida. The five presentations highlight durable responses in heavily pretreated patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL) and additional studies showing deep, rapid, and sustained undetectable minimal residual disease (uMRD) rates with sonrotoclax-based combinations in patients with treatment-naive chronic lymphocytic leukemi
Andersen Consulting tilføjer samarbejdsfirmaet Codezilla7.12.2025 21:19:00 CET | Pressemeddelelse
Andersen Consulting styrker sine kompetencer inden for digital transformation gennem en samarbejdsaftale med Codezilla, et firma med hovedsæde i Rumænien, der udvikler specialtilpasset software. Codezilla specialiserer sig i at udvikle skræddersyede softwareprodukter, der løser forretningsmæssige udfordringer gennem en tværfaglig tilgang, som kombinerer softwareudvikling med dybdegående marketingekspertise. Med over 30 år på markedet fungerer firmaet som implementerings- og digital konsulentressource for reklamebureauer, samtidig med at de arbejder med en bred kundebase, herunder virksomheder inden for sundhedssektoren og medicinsk udstyr. Codezillas interne teams strækker sig over teknik, design og strategi og leverer omnichannel-løsninger til både regionale og globale kunder. "Vi tror på, at fantastisk software er resultatet af solid ingeniørkunst og disciplineret eksekvering," udtaler Sebastian Doroftei, administrerende direktør for Codezilla. "Vores samarbejde med Andersen Consulti
Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 17:00:00 CET | Press release
AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom